CN112972668A - 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗 - Google Patents

重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗 Download PDF

Info

Publication number
CN112972668A
CN112972668A CN202110238900.XA CN202110238900A CN112972668A CN 112972668 A CN112972668 A CN 112972668A CN 202110238900 A CN202110238900 A CN 202110238900A CN 112972668 A CN112972668 A CN 112972668A
Authority
CN
China
Prior art keywords
mva
filovirus
seq
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110238900.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·沃克曼
罗宾·施泰格瓦尔德
H·霍赫赖因
U·迪迈尔
H·劳特巴赫
于尔根·豪斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN112972668A publication Critical patent/CN112972668A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/14011Filoviridae
    • C12N2760/14111Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/14011Filoviridae
    • C12N2760/14211Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202110238900.XA 2014-09-03 2015-09-03 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗 Pending CN112972668A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045538P 2014-09-03 2014-09-03
US62/045,538 2014-09-03
US201462055154P 2014-09-25 2014-09-25
US62/055,154 2014-09-25
CN201580047328.1A CN106999565B (zh) 2014-09-03 2015-09-03 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580047328.1A Division CN106999565B (zh) 2014-09-03 2015-09-03 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗

Publications (1)

Publication Number Publication Date
CN112972668A true CN112972668A (zh) 2021-06-18

Family

ID=54145734

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110238900.XA Pending CN112972668A (zh) 2014-09-03 2015-09-03 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗
CN201580047328.1A Active CN106999565B (zh) 2014-09-03 2015-09-03 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580047328.1A Active CN106999565B (zh) 2014-09-03 2015-09-03 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗

Country Status (14)

Country Link
US (2) US10576141B2 (2)
EP (1) EP3188752A2 (2)
JP (2) JP6823586B2 (2)
KR (2) KR102736868B1 (2)
CN (2) CN112972668A (2)
AU (2) AU2015310909B2 (2)
CA (1) CA2959105C (2)
IL (2) IL250552B (2)
MX (1) MX2017002791A (2)
MY (1) MY193417A (2)
SG (2) SG10201901735XA (2)
UA (1) UA126848C2 (2)
WO (1) WO2016034678A2 (2)
ZA (1) ZA201701077B (2)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型pb2遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
HK1247066A1 (zh) * 2014-11-26 2018-09-21 Neuravi Limited 从血管除去阻塞性血栓的取血栓装置
US11701418B2 (en) * 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
CN115300622A (zh) * 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
CN121159719A (zh) 2015-04-17 2025-12-19 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
WO2017120577A1 (en) 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
JP7053491B2 (ja) * 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用hpvワクチン組み合わせ
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
WO2018075978A1 (en) * 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2019018501A1 (en) * 2017-07-18 2019-01-24 Geovax Inc. COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
GB201716181D0 (en) * 2017-10-04 2017-11-15 Univ Cape Town Recombinant mva with modified hiv-1 env
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ctla-4変異型免疫調節タンパク質およびそれらの使用
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン(ha)タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
AU2019336940B2 (en) 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
US20220040284A1 (en) * 2018-09-28 2022-02-10 The Chancellor, Masters And Scholars Of The University Cambridge Vaccines and methods
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたnaを有する組換えインフルエンザウイルス
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
CN115819616B (zh) * 2021-07-28 2025-04-11 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
IL322961A (en) 2023-03-10 2025-10-01 Bavarian Nordic As Production of smallpox viruses from cell cultures
AU2024236322A1 (en) 2023-03-10 2025-08-21 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
WO2024188801A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production
WO2026006679A1 (en) * 2024-06-28 2026-01-02 The Regents Of The University Of California Retroviral vectors
CN120843742A (zh) * 2025-09-09 2025-10-28 军事科学院军事医学研究院军事兽医研究所 一种泛哺乳动物丝状病毒检测用引物组及其检测试剂盒和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2776391C (en) * 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
EP1586331B1 (en) * 2001-10-01 2008-05-28 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of a preventive vaccine for filovirus infection in primates
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
EP1797113B1 (en) * 2004-09-27 2014-11-26 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Optimized vaccines to provide protection against ebola and other viruses
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
EP3351628B1 (en) * 2008-10-24 2023-07-26 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
DK2352834T3 (en) * 2008-11-21 2017-03-13 Bavarian Nordic As VECTOR INCLUDING MULTIPLE HOMOLOGICAL NUCLEOTIDE SEQUENCES
US9097713B2 (en) * 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
US9526777B2 (en) * 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
CA3194125A1 (en) 2012-04-12 2013-10-17 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
GB201303406D0 (en) 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KEEFER M.C.等: "A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects", VACCINE, vol. 29, pages 1948 - 1958, XP028147197, DOI: 10.1016/j.vaccine.2010.12.104 *
LAUTERBACH H.等: "GeneticadjuvantationofrecombinantMVAwithCD40LpotentiatesCD8Tcellmediatedimmunity", FRONTIERS IN IMMUNOLOGY, vol. 4, pages 1 - 16 *
PRATT W.D.等: "Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus Vector", CLINCIAL AND VACCINE IMMUNOLOGY, vol. 17, no. 4, pages 572 - 581, XP002688256, DOI: 10.1128/CVI.00467-09 *

Also Published As

Publication number Publication date
BR112017003908A2 (pt) 2018-02-27
UA126848C2 (uk) 2023-02-15
US11338030B2 (en) 2022-05-24
KR102736868B1 (ko) 2024-12-02
JP6823586B2 (ja) 2021-02-03
KR102812180B1 (ko) 2025-05-23
JP2017527557A (ja) 2017-09-21
WO2016034678A3 (en) 2016-06-02
AU2021209228A1 (en) 2021-08-19
KR20230134155A (ko) 2023-09-20
EP3188752A2 (en) 2017-07-12
SG10201901735XA (en) 2019-03-28
US20170304427A1 (en) 2017-10-26
SG11201701506PA (en) 2017-03-30
JP2021063112A (ja) 2021-04-22
NZ729012A (en) 2023-12-22
JP7113924B2 (ja) 2022-08-05
CA2959105C (en) 2023-10-17
MX2017002791A (es) 2017-05-30
IL250552A0 (en) 2017-03-30
CA2959105A1 (en) 2016-03-10
AU2015310909A1 (en) 2017-03-02
CN106999565B (zh) 2021-03-05
US10576141B2 (en) 2020-03-03
IL290052A (en) 2022-03-01
IL250552B (en) 2022-02-01
KR20170048396A (ko) 2017-05-08
AU2015310909B2 (en) 2021-05-27
CN106999565A (zh) 2017-08-01
ZA201701077B (en) 2022-07-27
WO2016034678A2 (en) 2016-03-10
MY193417A (en) 2022-10-12
US20200268872A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP7113924B2 (ja) 組み換え改変ワクシニアウイルスアンカラ(mva)フィロウイルスワクチン
US5741492A (en) Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US10421978B2 (en) Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus
KR102264852B1 (ko) 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
KR20220154114A (ko) 백신 및 SARS-CoV2에 대한 면역 반응을 유도하기 위한 그의 용도
CA2777744C (en) Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
KR20230022206A (ko) 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신
EA039715B1 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
BR112017003908B1 (pt) Vacina contra filovírus de vírus de vaccinia modificado recombinante ankara (mva)
HK1108115A1 (en) Sars vaccine based on replicative vaccinia virus vector
HK1108115B (en) Sars vaccine based on replicative vaccinia virus vector
HK1205459B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210618